CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma

Jing Wei; Guanzhen Yu; Genbao Shao; Aiqin Sun; Miao Chen; Wannian Yang; Qiong Lin

doi:10.18632/oncotarget.8845

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma

Jing Wei _, Guanzhen Yu, Genbao Shao, Aiqin Sun, Miao Chen, Wannian Yang and Qiong Lin

PDF | HTML | How to cite

Oncotarget. 2016; 7:31067-31078. https://doi.org/10.18632/oncotarget.8845

Metrics: PDF 2172 views | HTML 2817 views | ?

Abstract

Jing Wei1, Guanzhen Yu2, Genbao Shao1, Aiqin Sun1, Miao Chen1,3, Wannian Yang1, Qiong Lin1

1School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China

2Changzheng Hospital, Shanghai, China

3The Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu, China

Correspondence to:

Qiong Lin, e-mail: [email protected]

Wannian Yang, e-mail: [email protected]

Keywords: gastric cardia adenocarcinoma, CYR61, prognostic biomarker, metastasis, cell migration

Received: January 04, 2016 Accepted: March 31, 2016 Published: April 20, 2016

ABSTRACT

Gastric cardia adenocarcinoma (GCA) is the most aggressive subtype of gastric cancer with a high metastatic rate. In this report, we collected tumor tissue samples from 214 GCA cases and examined expression of CYR61, a target gene product of the Hippo-YAP/TAZ pathway, in the GCA tumors by immunohistochemical (IHC) staining using the tissue microarray assay (TMA). The results have shown that CYR61 is overexpressed in 44% of the GCA tumor samples. Expression of CYR61 is inversely correlated with cumulative survival of GCA patients (p<0.001) and significantly associated only with metastatic pathological categories (with N category, p=0.052; with TNM stage, p=0.001). Furthermore, knockdown of CYR61 in gastric cancer AGS cells impairs the cancer cell migration and invasion, suggesting a driver role of CYR61 in metastasis. Thus, our studies have established CYR61 as a metastatic biomarker for prediction of poor prognosis of GCA and provided a potential molecular target for anti-metastatic therapy of GCA.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8845

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma

Abstract